Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
P/E Ratio
201
P/B Ratio
2.48
Industry P/E
--
Debt to Equity
0.16
ROE
0.01 %
ROCE
0.73 %
Div. Yield
0 %
Book Value
0.81
EPS
0.01
CFO
$-25.16 Mln
EBITDA
$-30.31 Mln
Net Profit
$-38.67 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Nephros (NEPH)
| 36.73 | 32.24 | 22.56 | -8.22 | -21.47 | -25.90 | -11.11 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Nephros (NEPH)
| -57.22 | 199.00 | -80.34 | -31.24 | -13.77 | 93.96 | 26.48 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 115.60 | 7,323.66 | 502.61 | 0 | |
| 211.94 | 11,487.64 | 28.56 | 16.69 | |
| 6.74 | 1,074.68 | -- | -96.27 | |
| 31.21 | 8,287.67 | 32.21 | 15.43 |
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants... from water and bicarbonate concentrate and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It provides medical device products such as the DSU-H and SSU-H which are in-line, 0.005-micron ultrafilters that give dual- and single-stage protection, respectively; S100 which is a point-of-use, 0.01-micron microfilter; and the HydraGuard and HydraGuard - Flush which are 0.005-micron cartridge ultrafilters that given single-stage protection, these products give protection from waterborne pathogens. Further, it provides the DSU-D, SSU-D, and SSUmini are in-line, 0.005-micron ultrafilters that provide protection from bacteria, viruses, and endotoxins; and the EndoPur, a 0.005-micron cartridge ultrafilter that provides single-stage protection from bacteria, viruses, and endotoxins. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Read more
President, CEO & Director
Mr. Robert Banks
President, CEO & Director
Mr. Robert Banks
Headquarters
South Orange, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nephros Inc (NEPH) stood at $ 11 Mln as on 31-Dec-24
The share price of Nephros Inc (NEPH) is $2.01 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Nephros Inc (NEPH) has given a return of -21.47% in the last 3 years.
Nephros Inc (NEPH) has a market capitalisation of $ 21 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Nephros Inc (NEPH) is 201.00 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nephros Inc (NEPH) and enter the required number of quantities and click on buy to purchase the shares of Nephros Inc (NEPH).
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, bacteria, cysts, particulates, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants. It provides medical device products such as the DSU-H and SSU-H which are in-line, 0.005-micron ultrafilters that give dual- and single-stage protection, respectively; S100 which is a point-of-use, 0.01-micron microfilter; and the HydraGuard and HydraGuard - Flush which are 0.005-micron cartridge ultrafilters that given single-stage protection, these products give protection from waterborne pathogens. Further, it provides the DSU-D, SSU-D, and SSUmini are in-line, 0.005-micron ultrafilters that provide protection from bacteria, viruses, and endotoxins; and the EndoPur, a 0.005-micron cartridge ultrafilter that provides single-stage protection from bacteria, viruses, and endotoxins. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
The CEO & director of Mr. Robert Banks. is Nephros Inc (NEPH), and CFO & Sr. VP is Mr. Robert Banks.
There is no promoter pledging in Nephros Inc (NEPH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,136
|
|
|
829
|
|
|
722
|
|
|
107
|
| Nephros Inc. (NEPH) | Ratios |
|---|---|
|
Return on equity(%)
|
0.87
|
|
Operating margin(%)
|
0.64
|
|
Net Margin(%)
|
0.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Nephros Inc (NEPH) was $0 Mln.
$0.05
(
